

Premarin® Family Published Review Papers

1. Creasman WT. Is There an Association Between Hormone Replacement Therapy and Breast Cancer? *Journal of Women's Health* 1998;7(10):1231–1246.
2. Nachtigall LE. Sex Hormone-Binding Globulin and Breast Cancer Risk. *Primary Care Update for Ob/Gyns* 1999;6(2):39–45.
3. Maddox RW. The New Science of Estrogen Receptors. *US Pharmacist* 1999;24(4):87–98. [CE Monograph.]
4. Birge SJ. Practical Strategies for the Diagnosis and Treatment of Alzheimer's Disease. *Clinical Geriatrics* 1999;7(4):56–74.
5. Curtis MG. Selective Estrogen Receptor Modulators: A Controversial Approach for Managing Postmenopausal Health. *Journal of Women's Health* 1999;8(3):321–334.
6. Daynes RA, Smith JA. Aging and Menopause: Targeting Strategies for Therapies (CME). *Clinical Geriatrics* 1999;7(9):56–65.
7. Sherwin BB. Mild Cognitive Impairment: Potential Pharmacological Treatment Options. *Journal of the American Geriatrics Society* 2000;48(4):431–441.
8. Dey M, Lyttle CR, Pickar JH. Recent Insights into the Varying Activity of Estrogens. *Maturitas* (Supplement) 2000;34:S25–S33.
9. Mosca L. Hormone Replacement Therapy in the Prevention and Treatment of Atherosclerosis. *Current Atherosclerosis Reports* 2000;2(4):297–302.
10. Mosca L. The Role of HRT in the Prevention of Postmenopausal Heart Disease. *Archives of Internal Medicine* 2000;160:2263–2272.
11. Snow KK, Seddon, JM. Age-Related Eye Diseases: Impact of Hormone Replacement Therapy and Other Risk Factors. *International Journal of Fertility (Women's Medicine Edition)* 2000;300–313.
12. Nachtigall LE. Hormone Therapy and Breast Cancer: Update 2000. *The Female Patient (Ob/Gyn Edition, CME)* 2000;25(10):77–83.
13. Nachtigall LE. Hormone Therapy and Breast Cancer: Update 2000. *The Female Patient (Primary Care Edition)* 2000;25(10):55–61.
14. Maddox R. Generic and Therapeutic Substitution. *NABP State Newsletter* [serial online], www.nabp.org, 4th quarter 2000;2–3.
15. Curtis MG. SERMs as an Alternative to Hormone Therapy? *Menopause Digest* 2000;12(4):27–28.

Updated December 14, 2001

Premarin® Family Published Review Papers

16. Ansbacher R. All Estrogens Are Not the Same for Postmenopausal Health. *American Journal of Obstetrics and Gynecology* 2001;184(3):255-263.
17. Gallagher JC. The Role of Estrogens in the Management of Postmenopausal Bone Loss. *Rheumatic Disease Clinics of North America* 2001;27(1):143-162.
18. Cefalu WT. The Use of Hormone Replacement Therapy in Postmenopausal Women with Type 2 Diabetes. *Journal of Women's Health and Gender-Based Medicine* 2001;10(3):241-256.
19. deVane P. Current Issues in Cardioprotective Effects of HRT. In: *Hormone Replacement Therapy and Cardiovascular Disease: The Current Status of Research and Practice*, A. R. Genazzani, Ed. Parthenon Publishing: London: May 2001.
20. Lobo RA, Whitehead MI. Is low-dose hormone replacement therapy for postmenopausal women efficacious and desirable? *Climacteric* 2001;4(2):110-119.
21. Thorneycroft IH. Prevention of Heart Disease in Women: Is Postmenopausal Estrogen Therapy Warranted (Point-Counterpoint). The HERS Trial Does Not Refute a Cardioprotective Effect of Hormone Replacement Therapy. *Menopause Management* 2001;July/Aug:16-28.
22. Bush TL, Whiteman M, Flaws J. Hormone Replacement Therapy and Breast Cancer: A Qualitative Review. *Obstetrics and Gynecology* 2001;98(3):498-508.

Clinical Trial Publications

1. Archer DF, Pickar JH. Hormone Replacement Therapy: Effect of Progestin Dose and Time Since Menopause on Endometrial Bleeding. *Obstetrics and Gynecology* 2000;96(6):899-905.
2. Maloney C, Oliver ML. Effect of Local Conjugated Estrogens on Vaginal pH and Urogenital Health in Elderly Women. *Journal of the American Medical Directors Association* 2001;2(2):51-55.
3. Utian WH, Shoupe D, Bachmann G, Pinkerton JV, Pickar JH. Relief of Vasomotor Symptoms and Vaginal Atrophy with Lower Doses of Conjugated Equine Estrogens and Medroxyprogesterone Acetate. *Fertility and Sterility* 2001;75(6):1065-1071.
4. Archer DF, Dorin M, Lewis V, Schneider DL, Pickar JH. Effects of Lower Doses of Conjugated Equine Estrogens and Medroxyprogesterone Acetate on Endometrial Bleeding. *Fertility and Sterility* 2001;75(6):1080-1087.
5. Pickar JH, Yeh I-T, Wheeler JE, Cunnane MF, Speroff L. Endometrial Effects of Lower Doses of Conjugated Equine Estrogens and Medroxyprogesterone Acetate. *Fertility and Sterility* 2001;76(1):13-24.

Updated December 14, 2001

Premarin® Family Published Review Papers

6. Lobo RA, Bush T, Carr BR, Pickar JH. Effects of Lower Doses of Conjugated Equine Estrogens and Medroxyprogesterone Acetate on Plasma Lipids and Lipoproteins, Coagulation Factors, and Carbohydrate Metabolism. *Fertility and Sterility* 2001;76(1):25-31.
7. Gambacciani M, Ciaponi M, Cappagli B, Genazzani A. Effects of Low-Dose, Continuous Combined Conjugated Estrogens and Medroxyprogesterone Acetate on Menopausal Symptoms, Body Weight, Bone Density, and Metabolism in Postmenopausal Women. *American Journal of Obstetrics and Gynecology* 2001;185(5):1180-1185.

Supplements

1. Speroff L, Gallagher JC, Raisz L, Montgomery Rice V, Pinkerton J. Menopause Management: The Impact of Low-Dose HRT. *Contemporary Ob/Gyn* 2001;Supplement (July).
2. Fiorica J, Editor. Postmenopausal Hormone Therapy and Breast Health: A Review for Clinicians *Women's Health in Primary Care* 2001;Supplement (October):5-36.
 - Introduction. J. Fiorica
 - Inconsistency in Epidemiologic Findings on Postmenopausal Hormone Therapy and Breast Cancer. L. Speroff
 - The Impact of HRT on Mammography. J. Fiorica
 - A Rationale for Estrogen Use in Breast Cancer Survivors. P. DiSaia
 - Mechanisms for Hormonal Regulation of Breast Tissue. J. Fiorica and B. Boman
 - Postmenopausal Hormone Therapy: Informed Patients, Shared Decisions. M. Blackwood, W. Creasman, and L. Speroff
 - Patient Education Handout
3. Andrews W. Trend to Lower Doses of ERT/HRT for the Management of Menopause. *ACOG Clinical Update* 2001;6(November/December):1-2, 13-14.

Updated December 14, 2001